You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Longitudinal analysis of treatment-induced genomic alterations in gliomas
|
|---|---|
| Published in |
Genome Medicine, February 2017
|
| DOI | 10.1186/s13073-017-0401-9 |
| Pubmed ID | |
| Authors |
E. Zeynep Erson-Omay, Octavian Henegariu, S. Bülent Omay, Akdes Serin Harmancı, Mark W. Youngblood, Ketu Mishra-Gorur, Jie Li, Koray Özduman, Geneive Carrión-Grant, Victoria E. Clark, Caner Çağlar, Mehmet Bakırcıoğlu, M. Necmettin Pamir, Viviane Tabar, Alexander O. Vortmeyer, Kaya Bilguvar, Katsuhito Yasuno, Lisa M. DeAngelis, Joachim M. Baehring, Jennifer Moliterno, Murat Günel |
| Abstract |
Glioblastoma multiforme (GBM) constitutes nearly half of all malignant brain tumors and has a median survival of 15 months. The standard treatment for these lesions includes maximal resection, radiotherapy, and chemotherapy; however, individual tumors display immense variability in their response to these approaches. Genomic techniques such as whole-exome sequencing (WES) provide an opportunity to understand the molecular basis of this variability. Here, we report WES-guided treatment of a patient with a primary GBM and two subsequent recurrences, demonstrating the dynamic nature of treatment-induced molecular changes and their implications for clinical decision-making. We also analyze the Yale-Glioma cohort, composed of 110 whole exome- or whole genome-sequenced tumor-normal pairs, to assess the frequency of genomic events found in the presented case. Our longitudinal analysis revealed how the genomic profile evolved under the pressure of therapy. Specifically targeted approaches eradicated treatment-sensitive clones while enriching for resistant ones, generated due to chromothripsis, which we show to be a frequent event in GBMs based on our extended analysis of 110 gliomas in the Yale-Glioma cohort. Despite chromothripsis and the later acquired mismatch-repair deficiency, genomics-guided personalized treatment extended survival to over 5 years. Interestingly, the case displayed a favorable response to immune checkpoint inhibition after acquiring mismatch repair deficiency. Our study demonstrates the importance of longitudinal genomic profiling to adjust to the dynamic nature of treatment-induced molecular changes to improve the outcomes of precision therapies. |
X Demographics
The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 30% |
| United Kingdom | 4 | 20% |
| Germany | 1 | 5% |
| Saudi Arabia | 1 | 5% |
| Canada | 1 | 5% |
| Montenegro | 1 | 5% |
| Russia | 1 | 5% |
| Australia | 1 | 5% |
| Unknown | 4 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 13 | 65% |
| Members of the public | 5 | 25% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
| Practitioners (doctors, other healthcare professionals) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Unknown | 66 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 16% |
| Researcher | 10 | 15% |
| Student > Bachelor | 8 | 12% |
| Other | 6 | 9% |
| Professor | 5 | 7% |
| Other | 9 | 13% |
| Unknown | 18 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 27% |
| Agricultural and Biological Sciences | 8 | 12% |
| Biochemistry, Genetics and Molecular Biology | 7 | 10% |
| Neuroscience | 5 | 7% |
| Nursing and Health Professions | 3 | 4% |
| Other | 4 | 6% |
| Unknown | 22 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 77. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2017.
All research outputs
#552,230
of 25,402,528 outputs
Outputs from Genome Medicine
#102
of 1,587 outputs
Outputs of similar age
#12,078
of 424,654 outputs
Outputs of similar age from Genome Medicine
#3
of 28 outputs
Altmetric has tracked 25,402,528 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,587 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.8. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 424,654 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.